The phase 3 Clinical Research of Developing PCSK9 Inhibitor as Cholesterol-Lowering Therapy in Chinese Patients with Dyslipidemia-1 (CREDIT-1) study showed that tafolecimab was safe and exhibited superior lipid-lowering efficacy compared to the placebo in non-FH patients [45]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.